Connect with us

Technology

Gastroesophageal Reflux Disease (GERD) Device Market to Reach USD 1.9 Billion by 2036 as Advanced Reflux Diagnostics and Minimally Invasive Procedures Improve Treatment Outcomes

Published

2 weeks ago

on

NEWARK, Del., July 1, 2026 /PRNewswire/ — The global Gastroesophageal Reflux Disease (GERD) Device Market, according to Future Market Insights, is entering a stable growth phase, driven by increasing adoption of reflux diagnostic tools, growing demand for minimally invasive anti-reflux procedures, and expanding hospital endoscopy infrastructure. The market is projected to grow from USD 1.3 billion in 2026 to USD 1.9 billion by 2036, registering a CAGR of 3.9% during the forecast period.

The market is evolving as healthcare providers increasingly prioritize objective reflux confirmation before selecting advanced treatment pathways. Device-assisted reflux management is gaining traction as physicians seek reliable diagnostic evidence through pH monitoring, manometry, and upper GI visualization.

Demand growth is being supported by rising GERD prevalence, increasing endoscopy volumes, and growing adoption of fundoplication and sphincter augmentation procedures in patients with persistent symptoms unresponsive to medication.

As clinical complexity increases, manufacturers with strong diagnostic platforms, physician training programs, reliable service networks, and minimally invasive treatment technologies are expected to secure long-term competitive advantage.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-1741

Market Overview

The GERD device market has become one of the most strategically important segments within gastrointestinal diagnostics and treatment. Market value is increasingly driven by advanced diagnostic systems that improve reflux confirmation accuracy and treatment devices that reduce long-term symptom burden.

The market is expected to rise from USD 1.3 billion in 2026 to USD 1.9 billion by 2036, supported by rising diagnostic demand and increasing adoption of device-assisted reflux interventions.

Unlike pharmaceutical therapies, GERD devices require specialized equipment, procedural expertise, and trained gastroenterology teams. Consequently, market leadership increasingly depends on suppliers capable of combining device innovation with workflow optimization and clinical support.

Key Growth Drivers

A major growth catalyst is the increasing need for objective reflux confirmation before advanced treatment decisions. Physicians are increasingly relying on pH monitoring, manometry, and endoscopy to distinguish GERD from other overlapping gastrointestinal and throat conditions.

Minimally invasive anti-reflux procedures are another major driver. Procedures such as fundoplication and magnetic sphincter augmentation offer long-term symptom control for refractory patients while reducing recovery time.

Growing hospital investments in upper GI imaging and diagnostic infrastructure are also accelerating device adoption by improving access to integrated diagnosis and treatment.

Rising GERD prevalence globally is further supporting market growth, especially as persistent reflux is increasingly associated with complications such as esophagitis and Barrett’s esophagus.

Technology & Innovation Trends

Innovation in the GERD device market is centered around patient-friendly diagnostics, minimally invasive procedures, and procedural efficiency.Wireless pH monitoring systems are improving diagnostic accuracy while enhancing patient comfort compared to traditional catheter-based systems.Advanced endoscopic visualization platforms are improving esophageal assessment and procedural planning, allowing clinicians to better identify anatomical reflux causes.Minimally invasive treatment technologies, including magnetic sphincter augmentation and radiofrequency ablation, are gaining adoption by offering lower procedural burden and faster recovery.Digital workflow integration and procedure guidance tools are becoming increasingly important for improving treatment precision and clinical outcomes.

Analyst Perspective

“GERD device demand is becoming an extension of structured reflux care rather than a substitute for medicine. Device adoption increases after persistent symptoms and stronger diagnostic proof from endoscopy or pH monitoring. Suppliers offering reliable diagnostics, procedural training, and service support will gain stronger hospital preference,” says FMI Analyst Anurag Sharma.

Market Challenges & Restraints

Despite stable growth potential, the market faces several structural challenges.

One major barrier is the high cost of advanced GERD procedures and implantable systems. Hospitals require specialized surgeons and sufficient procedure volume to justify investment.

Pricing pressure remains another major restraint, particularly as healthcare providers face reimbursement limitations and stricter capital expenditure controls.

Training complexity also constrains adoption, especially for advanced reflux procedures requiring specialized surgical expertise.

Regulatory approval requirements for novel treatment systems further increase commercialization timelines and market entry barriers.

Segment Analysis

The GERD device market is segmented by product type, procedure, end user, technology, distribution channel, and region.

By Product Type

Esophagoscopes and gastroscopes are projected to account for 42.0% market share in 2026, supported by strong demand for upper GI visualization in reflux diagnosis.

Other major product segments include:

Manometry SystemspH Monitoring SystemsFundoplication DevicesSphincter Augmentation DevicesRadiofrequency Ablation Devices

By Procedure

Fundoplication procedures are projected to account for 35.0% market share in 2026, supported by refractory GERD cases requiring anatomical correction.

Other key procedures include:

Diagnostic ProceduresRadiofrequency Thermal AblationMagnetic Sphincter Augmentation

By End User

Hospitals are expected to dominate demand with 60.0% market share in 2026, driven by integrated diagnostic and treatment capabilities.

Other end users include:

Diagnostic CentersAmbulatory Surgical Centers

By Technology

Minimally invasive technology is projected to account for 45.0% market share in 2026, driven by faster recovery and lower procedural burden.

Other technologies include:

Endoscopic TechnologyImplantable TechnologyEnergy-Based Technology

By Distribution Channel

Direct sales are expected to dominate with 58.0% market share in 2026, supported by account-based hospital procurement.

Other channels include:

DistributorsOnline Channels

Customize insights for your business strategy: https://www.futuremarketinsights.com/customization-available/rep-gb-1741

Regional Analysis

Regional growth increasingly depends on healthcare infrastructure, reflux diagnostic access, procedural capacity, and reimbursement dynamics.

United States remains the fastest-growing major market and is expected to grow at 5.2% CAGR through 2036, supported by broad reflux testing access and advanced procedural availability.India is the second-fastest growing market with 4.5% CAGR, driven by expanding hospital endoscopy infrastructure and rising private healthcare investments.China is forecast to grow at 3.6% CAGR, benefiting from structured medical device regulations and growing hospital diagnostic capacity.Brazil is projected to expand at 3.2% CAGR, supported by private hospital investments and stronger device traceability regulations.France, Germany, and United Kingdom maintain stable growth driven primarily by replacement demand and selective procedural upgrades.

Competitive Landscape

Competition is intensifying among global endoscopy manufacturers and specialized GERD device providers.

Competitive advantage increasingly depends on:

Diagnostic accuracyImaging qualityProcedural efficiencyTraining supportService reliability

As hospital procurement becomes more outcome-driven, suppliers must deliver value beyond standalone hardware.

Leading Companies Analysis

Key market participants include Olympus Corporation, Fujifilm Holdings Corporation, and PENTAX Medical, all of which maintain strong endoscopy portfolios and global service reach.

Other important participants include:

KARL STORZJohnson & Johnson MedTechMerit Medical SystemsLABORIEDiversatek

Investment & Strategic Developments

Investment activity is accelerating in wireless reflux diagnostics, minimally invasive treatment systems, and procedural workflow optimization.

Strategic focus is increasingly shifting toward improving diagnostic confidence and procedural efficiency.

Long-term investment is also focused on reducing procedural complexity and expanding access to advanced reflux care across ambulatory and regional centers.

Investors are paying close attention to diagnostic innovation, clinical evidence, and service coverage, as these factors strongly influence long-term commercial success.

Conclusion

The Gastroesophageal Reflux Disease (GERD) Device Market is transitioning from a niche reflux treatment segment into a high-value diagnostic and procedural care market.

With the market projected to grow from USD 1.3 billion in 2026 to USD 1.9 billion by 2036, long-term growth remains steady.

Demand is increasingly tied to diagnostic precision, minimally invasive treatment pathways, and operational reliability rather than conventional equipment alone. Companies capable of combining device innovation with strong clinical support and service infrastructure will be best positioned to lead the next phase of market growth.

Future Outlook

The MRI market is expected to become increasingly technology-driven over the next decade.

Future growth will be shaped by:

Expansion of AI reconstructionGrowth of low-helium MRI systemsIncreased portable MRI adoptionFaster scan workflowsStronger hospital replacement demand

The industry is likely to continue shifting toward high-efficiency imaging platforms with improved throughput and lower operational complexity.

Conclusion

The Magnetic Resonance Imaging (MRI) Market is transitioning from a conventional equipment replacement market into a high-value technology-driven diagnostic segment.

With the market projected to grow from USD 7.0 billion in 2026 to USD 10.2 billion by 2036, long-term growth remains steady.

Demand is increasingly tied to scan efficiency, AI-enabled workflows, and operational reliability rather than conventional hardware alone. Companies capable of combining imaging innovation with strong service and workflow support will be best positioned to lead the next phase of market growth.

Explore the Latest Healthcare Industry Analysis Now:  
https://www.futuremarketinsights.com/industry-analysis/healthcare   

FMI Custom Research: Strategic Intelligence for Confident Decision-Making 

In today’s rapidly evolving business environment, leadership teams need more than market data—they need clear, actionable intelligence tailored to their strategic objectives. FMI’s Custom Research solutions are designed around the specific business questions organizations need answered, enabling executives to evaluate growth opportunities, validate investments, assess competitive dynamics, and reduce uncertainty before making critical decisions. By combining deep industry expertise, primary research, and proprietary market intelligence, FMI delivers insights that help organizations move from assumptions to evidence-based strategies with greater speed and confidence. 

Key Executive Benefits 

Decision-Ready Insights: Research tailored to your specific business challenges, growth plans, and investment priorities. Reduced Strategic Risk: Validate market opportunities, customer demand, and competitive positioning before committing resources. Market Entry Confidence: Assess opportunity size, regulatory barriers, channel dynamics, and competitive landscapes with precision. Competitive Advantage: Gain proprietary intelligence unavailable through syndicated reports or internal datasets. Faster Growth Decisions: Accelerate expansion, product development, portfolio optimization, and investment planning. Primary Market Validation: Access real-world customer, buyer, and stakeholder insights that support high-confidence decision-making. Global Industry Expertise: Powered by 100+ analysts, 20,000+ published reports, and 1.6 million+ hours of research experience. Proven Track Record: Over 7,000 market-entry engagements completed across six regions and 14 industry sectors with strong client retention. 

Business Impact 

FMI helps organizations transform market complexity into strategic clarity, enabling leadership teams to identify growth opportunities faster, optimize resource allocation, strengthen competitive positioning, and make high-stakes business decisions with confidence. 

To explore how FMI Custom Research can support your strategic priorities, please connect with our team at – sales@futuremarketinsights.com  

Related Reports: 

Electrophysiology Market – https://www.futuremarketinsights.com/reports/electrophysiology-marketBattery Powered Surgical Drill Market – https://www.futuremarketinsights.com/reports/battery-powered-surgical-drill-marketEdema Management Devices Market – https://www.futuremarketinsights.com/reports/edema-management-devices-marketIsokinetic Diagnostic and Training System Market – https://www.futuremarketinsights.com/reports/isokinetic-diagnostic-and-training-system-marketViscosupplementation Market – https://www.futuremarketinsights.com/reports/viscosupplementation-market

About Future Market Insights (FMI)  

Future Market Insights (FMI) delivers actionable, decision-focused market intelligence that goes beyond traditional research reports. The company provides:  

In-depth pricing and cost benchmarking analysis  Demand forecasting based on real industry inputs  Procurement and buyer behavior insights  Supply chain and trade flow intelligence  Technology and application trend analysis across industries  

FMI follows a robust bottom-up research methodology, combining insights from industry experts, procurement leaders, manufacturers, and technical professionals to ensure accurate and practical market intelligence.  

For Press & Corporate Inquiries   

Rahul Singh    
AVP – Marketing and Growth Strategy    
Future Market Insights, Inc.    
+91 8600020075    
For Sales - sales@futuremarketinsights.com    
For Media - Rahul.singh@futuremarketinsights.com    
For web - https://www.futuremarketinsights.com/    
For Web - https://www.factmr.com/

Logo – https://mma.prnewswire.com/media/1197648/6020102/FMI_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/gastroesophageal-reflux-disease-gerd-device-market-to-reach-usd-1-9-billion-by-2036-as-advanced-reflux-diagnostics-and-minimally-invasive-procedures-improve-treatment-outcomes-302816004.html

SOURCE Future Market Insights

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Debevoise Expands Fund Finance Practice with the Return of Zahra Sowder as Partner

Published

16 minutes ago

on

July 14, 2026

By

NEW YORK, July 14, 2026 /PRNewswire/ — Debevoise & Plimpton LLP announced today that Zahra Sowder has joined the firm as a partner in its Fund Finance practice in New York.

Ms. Sowder advises private funds and financial institutions on a broad range of complex fund financing transactions, including subscription lines and NAV facilities, as well as bespoke financing solutions for LP and GP stakes. She also has extensive experience advising corporate borrowers on asset-based financings.

Presiding Partner Peter Furci said, “We continue to invest in our private capital platform to meet growing client demand for sophisticated financing solutions across the fund lifecycle. Zahra’s deep experience in this area, together with her longstanding connection to Debevoise and many of our clients, makes her an exceptional addition to the firm.”

Co-Chair of the Fund Finance Group Ramya Tiller said, “Private capital clients need sophisticated financing advice to support liquidity, fundraising and investment activity. Zahra has deep experience across the products our clients are using most actively, including NAV facilities across all strategies and other complex fund financing solutions. Having previously practiced at Debevoise, Zahra can contribute immediately to our growing practice.”

Ms. Sowder said, “Debevoise played an important role earlier in my career and is ideally suited for this next stage of my practice, especially given its specialized and growing fund finance practice. I look forward to working with colleagues and clients I know well and contributing to the continued growth of the practice.”

Ms. Sowder joins Debevoise from the New York office of another international law firm and previously practiced at Debevoise for more than 15 years as an associate and counsel. She received her J.D. from UCLA School of Law in 2008 and her B.A. from Vassar College in 2002.

View original content:https://www.prnewswire.com/news-releases/debevoise-expands-fund-finance-practice-with-the-return-of-zahra-sowder-as-partner-302825501.html

SOURCE Debevoise & Plimpton LLP

Continue Reading

Technology

As AI Agents Scale, Enterprises Demand Execution Control — Devenex Takes Control

Published

16 minutes ago

on

July 14, 2026

By

LAS VEGAS, July 14, 2026 /PRNewswire/ — • Inside the world’s largest organisations, AI agents are no longer experimental. They are executing in production — modifying financial records, triggering payments, approving workflows, and acting with the full operational authority of the enterprises that deployed them. By every credible estimate, the volume and consequence of these actions will increase by an order of magnitude within 24 months.

Yet no infrastructure layer exists to govern what these agents actually do. No systematic policy enforcement before action. No immutable audit trail after. No deterministic control between an agent’s intent and its real-world consequence. The most consequential technology shift in enterprise history is unfolding without an accountability layer.

Today, that changes. Devenex — the Execution Control Plane for AI agents — launches at Google Cloud Next 2026, introducing enterprise-grade governance infrastructure that sits between agent intent and real-world execution. Every action is policy-evaluated, explicitly authorised, identity-bound, and recorded as audit-grade evidence — before it takes effect, giving new life to enterprise AI initiatives.

Devenex is not a monitoring tool. It is not a workflow engine. It is the control plane that ensures no AI-initiated action executes without governance — giving CIOs, CTOs, CROs and enterprise security leaders the confidence to deploy agents at scale without sacrificing accountability.

THE STRUCTURAL GAP

Analyst consensus has converged on a single conclusion: enterprise AI execution capability is outpacing the controls designed to keep it accountable.

Gartner projects that by 2028, a third of enterprise software will incorporate agentic AI — up from less than one percent in 2024. McKinsey identifies governance and risk as the primary barriers to scaling enterprise AI, ahead of model quality or talent. Deloitte’s 2026 enterprise survey finds that 80 percent of leaders piloting AI agents cite security and compliance as the leading obstacle — up from 68 percent a year earlier.

The pattern is consistent across every credible source: enterprises are deploying agents faster than they can govern them. An AI agent that modifies a customer record, approves a discount, or initiates a wire transfer without a governing policy layer is not automation. It is an unmanaged compliance event, a latent security exposure, and a board-level liability.

Devenex addresses this gap at the infrastructure level — not as a feature bolted onto existing tools, but as a purpose-built control plane designed for governed enterprise execution from the ground up.

THE EXECUTION CONTROL PLANE

Devenex operates as the authorisation and governance layer between enterprise decision-making — whether initiated by humans, AI agents, or automated systems — and the execution of actions across enterprise systems of record.

Every action processed through Devenex produces four structured artifacts:

Intent Record. 

Execution Plan. 

Governed Execution. 

Execution Evidence. 

This model ensures that enterprises maintain full traceability from intent to outcome — satisfying EU AI Act, SOC 2, ISO 42001, and sector-specific regulatory requirements.

ENTERPRISE CAPABILITIES

Pre-Execution Policy Enforcement.  Every agent action is evaluated against organizational policy before execution. Nothing executes unchecked. Enterprises gain control over what agents are permitted to do — reducing compliance risk and eliminating ungoverned action.

Dynamic Human-in-the-Loop Governance.  High-consequence actions are routed to designated reviewers without halting low-risk automation. Approval workflows are configurable at the agent, action, or policy level — ensuring human oversight where it matters without creating operational bottlenecks.

Immutable Audit Infrastructure.  Every governed execution is recorded to an append-only ledger. Enterprises gain continuous compliance evidence without manual reporting.

Unified Observability Across Agents.  Live and retrospective visibility into agent activity, policy adherence, and anomaly patterns. Security, compliance, and operations teams share a single authoritative view of enterprise execution.

BUILT FOR ENTERPRISE REALITY

Devenex delivers flexible deployment models—SaaS, hybrid, and self-deployed—enabling organizations to adopt at their own pace.

Engineered to be framework-agnostic and cloud-native, Devenex integrates seamlessly across diverse enterprise environments. The platform does not replace existing systems of record, integration platforms, or identity providers. It governs execution across them.

LEADERSHIP

“For four decades, Abacus has earned the trust of enterprises navigating their most consequential technology transitions. Devenex represents the next chapter — purpose-built infrastructure for a world where AI agents execute with the authority of the organisations that deploy them. Governance at this layer is not optional. It is a precondition for enterprise AI at scale.”

— Aly Kuly Khan
Co-Founder & Chairman, Devenex

“For four decades, we’ve built the layers enterprises run on — systems of record, integration, workflow automation, API and iPaaS governance. Each wave solved the problem the previous one created. Today, AI agents are executing actions on architecture that was never designed to govern them. This isn’t an AI problem. It’s an architectural gap — and it’s the one our experience has prepared us to solve. Enterprises cannot answer four questions about any agentic action: who authorized it, what policy governed it, why it executed as it did, and whether they can prove it after the fact. In regulated environments, these aren’t edge cases — they’re the baseline. Devenex is the execution control plane that answers all four, by design, at execution time.”

— Shoaib A. Khan
Co-Founder & CEO, Devenex

AVAILABILITY & ENGAGEMENT

Devenex is available immediately, with deployment support from Abacus teams across the globe.

Enterprise pilot programmes are open to qualified organisations seeking to bring governed execution to production AI workloads.

Learn more at www.devenex.com

THE ROAD AHEAD

Enterprise AI is entering its execution era. The question is no longer whether agents can act — it is whether they can act accountably. The organisations that solve this first will scale AI faster, operate with greater confidence, and carry less risk than those that treat governance as a downstream problem.

Devenex exists to make governed execution the default operating model of the enterprise. Not as an aspiration. As infrastructure.

About DevenEx

Devenex is the Execution Control Plane for AI agents — enterprise infrastructure that governs every action across systems with policy enforcement, explicit authorisation, and audit-grade evidence. Built for the agentic era, Devenex sits between intent and execution so that no enterprise action moves forward ungoverned. Devenex is built by the team behind Abacus, bringing four decades of enterprise trust to AI execution governance.

About Abacus

Abacus is a global professional services leader in technology, outsourcing, and people solutions. With nearly 40 years of experience, 5,000+ professionals across four continents, and 1,500+ enterprise clients, Abacus designs bespoke solutions that enable organisations to create the future of business and embrace change for sustainable growth.

Media Contact

Devenex
www.devenex.com
Shoaib Khan
shoaib.khan@abacuscambridge.com
+1 (347) 701-4221

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/as-ai-agents-scale-enterprises-demand-execution-control–devenex-takes-control-302825507.html

Continue Reading

Technology

CASIO Makes Classroom-Ready Calculator Free for Everyone with Launch of fx-300ES PLUS Online Emulator

Published

16 minutes ago

on

July 14, 2026

By

Casio’s fx-300ES PLUS Online Emulator is the First Web-Accessible Emulator of the Iconic Scientific Calculator, Giving Students, Parents and Teachers Free, Instant Access

JERSEY CITY, N.J., July 14, 2026 /PRNewswire/ — Casio America, Inc. today announced a free online emulator for its fx-300ES PLUS scientific calculator, available now at ClassPad.net. The first web-accessible emulator of its kind for the fx-300ES series gives students and educators instant access to a fully functional digital calculator—at no cost—from any internet-connected device.

“The 300ES PLUS has been a staple in math and science classrooms for years because it’s reliable and easy to use,” said Marko Wityk, Senior General Manager of EdTech at Casio America. “This emulator takes that same experience and makes it available to any student. Whether they’re finishing homework or teachers are walking a class through a problem, this tool removes any barriers standing in the way of learning.”

Designed for Classrooms

The emulator requires only a free login through Google, Google Classroom, Microsoft, or Clever, platforms already in use at schools nationwide. Users gain access to a fully functional digital calculator replicating the fx-300ES PLUS, along with other scientific and graphing calculator options from Casio.

Key features include:

Projection mode – The emulator screen can be enlarged for display on a projector or interactive whiteboard, letting teachers walk the entire class through problems step-by-step.Key log – Displays a running log of each key used in a problem, allowing students to easily follow along with the teacher.Natural Textbook Display – See math problems and fractions exactly as they would appear in textbooks, homework, or exams.Zero cost and instant access – No app download needed and no purchase or subscription required now or in the foreseeable future.Device-agnostic – Compatible with any web-enabled device, from school Chromebooks to home laptops to tablets and other mobile devices.Screenshot – Capture an image of the calculator display to compare results and functions. Screenshots are copied to the clipboard for use in other applications as well.

The fx-300ES PLUS emulator is available now, free of charge, at ClassPad.net. Users can log in with an existing Google, Google Classroom, Microsoft, or Clever account. No additional registration is required.

The physical calculator remains available at major retailers nationwide and online at casio.com, typically priced around $15. Education pricing is available to teachers and schools by contacting edtech@casio.com.

About Casio America, Inc.
Casio America, Inc. is a subsidiary of Casio Computer Co., Ltd., one of the world’s leading manufacturers of consumer electronics and business equipment solutions. Casio’s EdTech division is dedicated to empowering students, educators, and parents with tools that make learning more accessible and effective. Casio products are sold through authorized Casio dealers. For more information, visit casio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/casio-makes-classroom-ready-calculator-free-for-everyone-with-launch-of-fx-300es-plus-online-emulator-302825523.html

SOURCE Casio America, Inc.

Continue Reading

Trending